Mohammed Alsaggaf
Pulmonary Disease · Olean, NYNPI 1750816021
Payments from drug & device makers
Across 133 payments — averaging $22.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$450
- GSK$370
- Sanofi$229
- Inspire Medical Systems, Inc.$225
- Insmed, Inc.$190
- Itamar Medical Inc$166
- plus $1K from 17 others
What the payments were for
- Food & beverage$2,81193%
- Education$2237%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 21 | $450 |
| GSK | 29 | $370 |
| Sanofi | 8 | $229 |
| Inspire Medical Systems, Inc. | 7 | $225 |
| Insmed, Inc. | 15 | $190 |
| Itamar Medical Inc | 2 | $166 |
| Boston Scientific | 1 | $145 |
| Viatris Specialty LLC | 7 | $141 |
| Regeneron Healthcare Solutions, Inc. | 6 | $141 |
| Actelion Pharmaceuticals US, Inc. | 3 | $139 |
| Mallinckrodt Hospital Products Inc. | 4 | $118 |
| Grifols USA, LLC | 6 | $112 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $100 |
| Harmony Biosciences LLC | 1 | $100 |
| Boehringer Ingelheim | 3 | $93 |
| Mylan Specialty L.p. | 3 | $67 |
| Amgen | 3 | $62 |
| Electromed, Inc. | 4 | $61 |
| Verona Pharma, Inc. | 2 | $40 |
| Vifor Pharma, Inc. | 1 | $25 |
| Ambu Inc. | 1 | $24 |
| United Therapeutics Corporation | 1 | $20 |
| Merck | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,034 in reported general payments places this provider in the 65th percentile of 1,115 pulmonary disease providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Albuterol Sulfate HfaAlbuterol Sulfate | 19 | $400 |
| Azithromycin | 13 | $76 |
| Prednisone | 12 | $16 |
Paid to pharmacies, not to this prescriber.
Other pulmonary disease in Olean
- Linda RogersNew York$7.1M
- Maria PadillaNew York$3.6M
- R WhiteRochester$3.1M
- Juan WisniveskyNew York$3M
- Bushra MinaNew York$2.5M
- Robert KanerNew York$2.3M
- Negin HajizadehGreenport$2M
- Doreen Addrizzo-HarrisNew York$1.9M
- Sherif El BayadiSyracuse$1.9M
- Daniel LachantRochester$1.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.